{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:54:24Z","timestamp":1793404464202,"version":"4.5.0"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer"},{"name":"Bristol-Myers Squibb\/Pfizer"},{"name":"DAIICHI Sankyo"},{"name":"CSL Behring"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Direct oral anticoagulants (DOACs) are increasingly used worldwide. Little is known so far about their pharmacokinetics in emergency situations.<\/jats:p><jats:p>\n          Methods\u2003A prospective, observational registry was performed to determine the clinical course in consecutive patients with major bleeding or urgent surgery treated with DOACs. In samples collected as part of routine care DOAC drug concentrations were measured using ultraperformance liquid chromatography-tandem mass spectrometry. Anticoagulant intensity at first presentation and drug half-life (t\n          1\/2), tested in repeat samples, were evaluated.<\/jats:p><jats:p>\n          Results\u2003A total of 140 patients were prospectively included. Pharmacokinetic data were available in 94% (132\/140) of patients. Note that 67% (89\/132) experienced life-threatening bleeding and 33% (43\/132) needed an urgent surgery. For pharmacokinetic analysis a total of 605 blood samples was available. Median concentration on admission was 205\u2009ng\/mL for rivaroxaban and 108\u2009ng\/mL for apixaban. All treatment groups showed a high variation of drug concentrations at baseline. In rivaroxaban-treated patients t\n          \u00bd was 17.3\u2009hours (95% confidence interval [CI]: 15.4\u201319.7) without significant difference in both groups (major bleeding: t\n          \u00bd 16.7\u2009hours, 95% CI: 14.7\u201319.3; urgent surgery: t\n          \u00bd 19.7\u2009hours, 95% CI: 15.2\u201327.9; p\u2009=\u20090.292). In apixaban-treated patients t\n          \u00bd was 25.0\u2009hours (95% CI: 22.9\u201327.6) with a longer t\n          \u00bd after urgent surgery (t\n          1\/2: 30.8\u2009hours; 95% CI: 26.9\u201336.4) compared with severe bleeding (t\n          1\/2: 20.8\u2009hours; 95% CI: 18.8\u201323.2; p\u2009&lt;\u20090.001).<\/jats:p><jats:p>\n          Conclusion\u2003Emergency patients under DOAC treatment show a high variation of anticoagulant concentrations at baseline. Compared with rivaroxaban, apixaban showed a lower median concentration on admission and a longer t\n          \u00bd.<\/jats:p>","DOI":"10.1055\/a-1549-6556","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:04:25Z","timestamp":1626217465000},"page":"552-559","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry"],"prefix":"10.1055","volume":"122","author":[{"given":"Edelgard","family":"Lindhoff-Last","sequence":"first","affiliation":[{"name":"Coagulation Centre at the Cardiology Angiology Centre Bethanien Hospital (CCB), Frankfurt, Germany"},{"name":"Coagulation Research Centre Bethanien Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Birschmann","sequence":"first","affiliation":[{"name":"Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Centre, Ruhr University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Centre, Ruhr University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lindau","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-7279","authenticated-orcid":false,"given":"Stavros","family":"Konstantinides","sequence":"additional","affiliation":[{"name":"Center for Thrombosis and Haemostasis (CTH), Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grottke","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Nowak-G\u00f6ttl","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, Thrombosis & Haemostasis Treatment Centre, University Hospital, Kiel-L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lucks","sequence":"additional","affiliation":[{"name":"Coagulation Research Centre Bethanien Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zydek","sequence":"additional","affiliation":[{"name":"Coagulation Research Centre Bethanien Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Heymann","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Intensive Care Medicine, Emergency Medicine and Pain Therapy, Vivantes Klinikum im Friedrichshain, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"S\u00fcmnig","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, Universit\u00e4tsmedizin, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[{"name":"Thrombosis Research Unit, Department of Medicine 1, Dresden, Germany"},{"name":"Division of Haematology, Dresden University Clinic, Dresden, Germany"},{"name":"Department of Haematology and Oncology, Kings College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schellong","sequence":"additional","affiliation":[{"name":"Medical Department 2, Municipal Hospital, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Meybohm","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany"},{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine, Universit\u00e4tsmedizin, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Mathematical Modelling, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"ref4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"ref5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"J Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2016.06.003","article-title":"Bleeding with direct oral anticoagulants vs warfarin: clinical experience","volume":"129","author":"J Eikelboom","year":"2016","journal-title":"Am J Med"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1111\/jth.15104","article-title":"The relationship between DOAC levels and clinical outcomes: the measures tell the tale","volume":"18","author":"M MA Toorop","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5482\/HAMO-16-11-0043","article-title":"Direct oral anticoagulants (DOAC) - management of emergency situations","volume":"37","author":"E Lindhoff-Last","year":"2017","journal-title":"Hamostaseologie"},{"issue":"20","key":"ref11","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2012-12-453076","article-title":"The laboratory and the direct oral anticoagulants","volume":"121","author":"A Tripodi","year":"2013","journal-title":"Blood"},{"issue":"31","key":"ref12","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study","volume":"38","author":"A Godier","year":"2017","journal-title":"Eur Heart J"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ana.25165","article-title":"Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage","volume":"83","author":"D J Seiffge","year":"2018","journal-title":"Ann Neurol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"R C Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"issue":"18","key":"ref15","first-page":"312","article-title":"Severe hemorrhage associated with oral anticoagulants","volume":"117","author":"E Lindhoff-Last","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cca.2018.08.017","article-title":"Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays","volume":"486","author":"J Kuhn","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ALN.0000000000001631","article-title":"Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis","volume":"127","author":"P Albaladejo","year":"2017","journal-title":"Anesthesiology"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1024\/0301-1526\/a000777","article-title":"Reversal strategies in patients treated with direct oral anticoagulants","volume":"48","author":"P Gressenberger","year":"2019","journal-title":"Vasa"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40266-018-0609-4","article-title":"Serum concentrations and elimination rates of direct-acting oral anticoagulants (DOACs) in older hip fracture patients hospitalized for surgery: a pilot study","volume":"36","author":"K K Viktil","year":"2019","journal-title":"Drugs Aging"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FTD.0000000000000594","article-title":"Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand?","volume":"41","author":"E Wieland","year":"2019","journal-title":"Ther Drug Monit"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-9560-12-22","article-title":"Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism","volume":"12","author":"S Harder","year":"2014","journal-title":"Thromb J"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/1389200218666170424151551","article-title":"Apixaban - metabolism, pharmacologic properties and drug interactions","volume":"18","author":"P Kubisz","year":"2017","journal-title":"Curr Drug Metab"},{"issue":"19","key":"ref24","doi-asserted-by":"crossref","first-page":"e017316","DOI":"10.1161\/JAHA.120.017316","article-title":"Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study","volume":"9","author":"A J Tafur","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"ref25","first-page":"19","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"2021","author":"J Douxfils","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1549-6556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:42:27Z","timestamp":1660142547000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1549-6556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":25,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1549-6556","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,13]]},"published":{"date-parts":[[2021,7,13]]}}}